
Brand Name | Status | Last Update |
|---|---|---|
| trovan | 2006-02-06 |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | — | 1 | 1 |
| Staphylococcal infections | D013203 | — | A49.01 | — | — | — | — | 1 | 1 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | — | — | 1 | 1 |
| Endocarditis | D004696 | EFO_0000465 | I33 | — | — | — | — | 1 | 1 |
| Staphylococcus aureus | D013211 | NCBITaxon_1280 | — | — | — | — | — | 1 | 1 |
| Drug common name | Trovafloxacin |
| INN | trovafloxacin |
| Description | Trovafloxacin is a 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure. It has a role as an antimicrobial agent, a hepatotoxic agent, a topoisomerase IV inhibitor, a DNA synthesis inhibitor and an antibacterial drug. It is a 1,8-naphthyridine derivative, an amino acid, a monocarboxylic acid, an azabicycloalkane, a tertiary amino compound, a primary amino compound, a quinolone antibiotic, a fluoroquinolone antibiotic and a difluorobenzene. It is a conjugate base of a trovafloxacin(1+). |
| Classification | Small molecule |
| Drug class | antibacterials (quinolone derivatives) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | N[C@H]1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12 |
| PDB | — |
| CAS-ID | 147059-72-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL428 |
| ChEBI ID | 9763 |
| PubChem CID | 62959 |
| DrugBank | DB00685 |
| UNII ID | 9F388J00UK (ChemIDplus, GSRS) |






